At Fall Clinical 2026, Neal Bhatia, MD, discussed cycle therapy for actinic keratosis, red light photodynamic therapy for superficial basal cell carcinoma, and clinical research pitfalls
|Articles|January 3, 2008
Per agreement with Galderma, Anika reaquires rights to Elevess dermal filler products
Bedford, Mass. - Anika Therapeutics, based here, announced that Anika and Galderma have finalized their agreement to terminate all license, development and supply arrangements involving the Elevess family of filler products, reports MedicalNewsToday.com.
Advertisement
Bedford, Mass. - Anika Therapeutics, based here, announced that Anika and Galderma have finalized their agreement to terminate all license, development and supply arrangements involving the Elevess family of filler products, reports MedicalNewsToday.com.
The result is that Anika has now reacquired the worldwide rights to the future development and marketing of Elevess, including ownership of the trademark and all related packaging, marketing and promotional materials, as well all clinical studies, marketing research and training materials developed by Galderma.
MedicalNewsToday quotes Anika Vice President Gregory T. Fulton as saying, “We have begun moving forward in the search for a new partner for Elevess. There has been considerable interest expressed already by new potential partners, and we are actively pursuing these opportunities. In addition, we are continuing with pre-launch activities, which include reaching out to key opinion leaders. We plan to launch Elevess in the first half of (2008) and are confident that we will execute on our strategy to make dermal fillers an important franchise for the company.”
According to Anika, hyaluronic acid-based Elevess is the first injectable soft-tissue filler for facial wrinkles, scar remediation and lip augmentation to incorporate lidocaine. Elevess has been approved for sale in the United States, the European Union and Canada.
Advertisement
Related to this article
Day 3 of Fall Clinical 2026 featured roflumilast data in genital psoriasis, long-term JAK inhibitor safety in atopic dermatitis, and expert insights on setting expectations in HS, treating advanced cSCC, and screening aesthetic patients.
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations above 3 times the upper limit of normal.
Patients with plaque psoriasis treated with roflumilast cream or foam reported greater improvements in sexual function and relationships vs vehicle, including those with genital involvement at baseline.
The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results, along with 3-year nemolizumab findings, upadacitinib switch data, and expert guidance on choosing a biologic in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
At week 112, at least 72% of patients on icotrokinra held PASI 90 and at least 44% held PASI 100, with no new safety signals reported.
Advertisement
Advertisement
Trending on Dermatology Times
1
JAK Inhibitor Safety in Atopic Dermatitis: Long-Term Epidemiology Data
2
Roflumilast Eases Sexual Difficulties in Psoriasis With Genital Involvement
3
No Observed Skin Lesion Flares After Switching to Upadacitinib in Atopic Dermatitis
4
Managing Treatment Expectations in Hidradenitis Suppurativa: What to Tell Patients Before Starting Therapy
5